NCT05504837View on ClinicalTrials.gov

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Cystic Fibrosis
Interventions
BIOLOGICAL

KB407 (Nebulization)

Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR

Trial Locations (5)

10028

RECRUITING

Northwell Health Physicians, New York

10532

RECRUITING

New York Medical College/ Boston Children's Health Physicians, Hawthorne

27157

RECRUITING

Atrium Health Wake Forest Baptist Medical Center, Winston-Salem

32610

RECRUITING

University of Florida, Gainesville, Gainesville

60093

RECRUITING

The Cystic Fibrosis Institute, Northfield

Sponsors
All Listed Sponsors
lead

Krystal Biotech, Inc.

INDUSTRY

NCT05504837 - A Study Assessing KB407 for the Treatment of Cystic Fibrosis | Biotech Hunter | Biotech Hunter